Examples
Worked examples
- Is an instance
A university-based oncologist designs a Phase 2 trial testing an already-FDA-approved drug at a new dose and schedule for an indication outside its approved label. No pharmaceutical company is sponsoring the study, so the oncologist submits the IND to FDA individually, becomes the sponsor-investigator, and is responsible for both the sponsor-side duties (IND maintenance, safety reporting to FDA, selecting and monitoring any additional participating sites) and the investigator-side duties (protocol conduct, informed consent, IRB reporting) for the entire trial.
- Is an instance
A surgeon at an academic medical center wants to run a randomized trial comparing two already-marketed surgical devices head to head. Because the comparison itself, not either device's approved use, is the novel element requiring study, the surgeon determines an IDE is needed, submits it under 21 CFR 812 as sponsor-investigator, and works with the institution's Clinical Trials Unit and IRB to build the multisite regulatory and monitoring infrastructure a company sponsor would otherwise supply.
Counter-examples
Looks similar, but isn't
- Not an instance
A hospitalist enrolls patients at their site into a Phase 3 trial designed by a pharmaceutical company, using the company's protocol, IND, and case report forms, and signs Form 1572 as the participating-site investigator. Because the company, not the hospitalist, initiated the trial and holds the IND as sponsor of record, this is industry-sponsored multi-site research, not an investigator-initiated study, even though the hospitalist is unambiguously an investigator on the trial.
Editorial commentary
An investigator-initiated study (IIS) — also called an investigator-initiated trial (IIT) — is a clinical trial that an individual investigator, rather than a pharmaceutical or device company, designs, initiates, and takes primary regulatory responsibility for conducting. The distinction is not simply that an academic clinician is involved (nearly every clinical trial has one); it is that the investigator originates the research question and protocol and holds the regulatory authorization to conduct it: the Investigational New Drug (IND) application for a drug or biologic trial, or the Investigational Device Exemption (IDE) for a device trial. That combination of roles creates a distinct regulatory category under FDA rules: the sponsor-investigator.
What Makes a Study “Investigator-Initiated”
An IIS is defined by who originates and holds regulatory authority for the trial, not by who happens to see patients. Under 21 CFR 312.3, FDA defines a sponsor as “a person who takes responsibility for and initiates a clinical investigation,” and an investigator as “an individual who actually conducts a clinical investigation.” Ordinarily those are two different parties — a pharmaceutical company sponsors, and physicians at participating sites investigate. In an IIS, the same person does both: the same regulation defines a sponsor-investigator as “an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed.” The device-trial equivalent, 21 CFR 812.3, defines a sponsor-investigator in materially the same terms for an investigation conducted under an IDE.
IISs are common where a commercial sponsor has no direct financial interest in the specific question being asked — a new dose or schedule for an already-approved drug, a head-to-head comparison of two marketed products, a novel combination, or a mechanistic or comparative-effectiveness question — but the study still meets FDA’s threshold for requiring an IND or IDE. (Not every academic study of a drug or device needs one; FDA’s own criteria for when human research can proceed without an IND are a separate determination the sponsor-investigator and their institution’s regulatory office typically make before the study is designed.)
The Sponsor-Investigator: Two Regulatory Roles, One Person
Because a sponsor-investigator meets both definitions at once, FDA regulations require them to fulfill both sets of obligations under 21 CFR Part 312, Subpart D (drugs/biologics) or the parallel structure in Part 812 (devices) — there is no reduced or combined obligation just because one person holds both roles.
| As sponsor | As investigator |
|---|---|
| File and maintain the IND/IDE, including required amendments (§312.23) | Conduct the study according to the investigational plan and current protocol (§312.60) |
| Select and qualify any additional investigators/sites, and monitor their conduct of the study (§312.53, §312.56) | Maintain control over and proper disposition of the investigational drug or device (§312.61) |
| Submit IND safety reports and annual reports to FDA (§312.32, §312.33) | Maintain investigator records and case histories for each subject (§312.62) |
| Maintain sponsor-side records and make them available for FDA inspection (§312.57, §312.58) | Report adverse events and study progress, including immediate reporting of serious adverse events to the sponsor role regardless of causality (§312.64, §312.64(b)) |
| Ensure IRB review is obtained and maintained for the study (§312.55, in coordination with §312.66) | Ensure informed consent is obtained and documented for every subject, and cooperate with any FDA inspection of investigator records (§312.66, §312.68) |
In practice, this means a sponsor-investigator files IND safety reports to FDA and receives and evaluates that same safety information as the reporting investigator; approves protocol amendments as sponsor and implements them as investigator; and is the point of FDA inspection for both sponsor-side records (Bioresearch Monitoring inspections of the IND) and investigator-side records (site inspections) if either occurs.
A related practical question institutions handle inconsistently is whether a sponsor-investigator must complete FDA Form 1572 (Statement of Investigator) for their own study. Form 1572 exists to document a sponsor’s confirmation that an investigator is qualified — a slightly awkward fit when the same person occupies both roles. Many institutional research-compliance offices still require the sponsor-investigator to complete one for the site file, both as a matter of internal documentation practice and because it is a convenient, FDA-recognized way to compile the qualifications and commitments information §312.23(a)(6)(iii)(b) otherwise requires the IND to contain; this is an institutional and practical convention rather than a separately stated regulatory mandate distinct from the underlying IND-content requirement.
Investigator-Initiated Study vs. Participating as a Site in an Industry-Sponsored Trial
The same clinician can be “an investigator” in both scenarios, which is why the two are easy to conflate:
- Investigator-initiated study: the investigator originates the protocol and research question, holds the IND/IDE as sponsor-investigator, and carries both sponsor- and investigator-side regulatory obligations — even if a company later provides drug supply or grant funding for the study, as long as the investigator retains the IND/IDE and sponsor role.
- Participating site in an industry-sponsored trial: a pharmaceutical or device company designs the protocol, holds the IND/IDE as sponsor of record, and the site investigator signs Form 1572 as one of potentially many participating-site investigators, carrying only the investigator-side obligations under §312.60–312.69.
Company-provided drug supply or grant funding for an academic-designed study does not, by itself, make a trial industry-sponsored — the operative fact is who holds the IND/IDE and the sponsor role, not who pays for supplies. Some companies do formally take over IND/IDE sponsorship of a study an investigator originated; at that point the study is no longer investigator-initiated in the regulatory sense, whatever it is called informally.
How Institutions Support Investigator-Initiated Studies Administratively
Because a sponsor-investigator personally carries obligations that a company sponsor would otherwise staff with dedicated regulatory, safety, and monitoring teams, academic institutions typically build shared infrastructure around IIS/IIT administration rather than leaving each investigator to build sponsor-side capacity alone:
- Clinical Trials Unit (CTU): many academic medical centers route IIS/IIT support through a Clinical Trials Unit, which provides the regulatory, monitoring, data-management, and IND/IDE-maintenance support a sponsor-investigator needs but does not have to build independently — a documented pattern in the academic clinical-trials literature, where CTUs supporting investigator-initiated trials tend to offer broader regulatory and management infrastructure than what a commercial sponsor typically expects a site to provide on its own.
- IRB: the Institutional Review Board reviews and continues to oversee the protocol regardless of sponsor structure, but for an IIS the sponsor-investigator (not a separate company regulatory-affairs team) is the party responsible for keeping the IRB informed of safety findings and protocol changes on the sponsor side of the relationship.
- Sponsored programs / research administration office: handles the contract and budget mechanics around any funding supporting the study (a grant, a company drug-supply agreement, or institutional funds) separately from the FDA regulatory relationship, which stays with the sponsor-investigator.
- Data and safety monitoring: higher-risk IISs commonly use a Data Safety Monitoring Board (DSMB) to provide the independent safety-review function a company sponsor’s internal safety team would otherwise perform.
- Registration and reporting: the sponsor-investigator is responsible for the study’s clinical trial registration and results reporting, the same obligation a commercial sponsor would otherwise own.
These functions do not remove the sponsor-investigator’s personal regulatory accountability — FDA’s inspection and enforcement authority still runs to the named individual who holds the IND/IDE — but they materially reduce the administrative burden of building sponsor-side capacity from nothing for each new study.
Frequently Asked Questions
Who can be a sponsor-investigator?
Under 21 CFR 312.3 and 812.3, a sponsor-investigator must be an individual (the definition explicitly excludes any entity other than a person) who both initiates and actually conducts the investigation. An institution, department, or company cannot itself be the “sponsor-investigator” — it can only be a sponsor, with a separate person as investigator.
Does an investigator-initiated study always require an IND or IDE?
No. An IIS only requires an IND or IDE if the study meets FDA’s underlying criteria for needing one at all — generally, human research involving a drug or device that is unapproved for the studied use, or that otherwise falls outside FDA’s exemption criteria. Many academic studies of approved products, within their approved use and at approved doses, proceed without an IND. Whether a specific IIS needs one is a determination the sponsor-investigator and the institution’s regulatory affairs office make before the study is designed, not something that follows automatically from academic origin.
Is IIS the same as IIT?
Yes — “investigator-initiated study” and “investigator-initiated trial” describe the same regulatory arrangement and are used interchangeably in practice; neither is a formally defined FDA regulatory term itself (the regulatory term is “sponsor-investigator,” describing the role that makes a study investigator-initiated).
Can an investigator-initiated study become multi-site?
Yes. A sponsor-investigator can add participating sites under their IND/IDE, in which case they take on the sponsor’s obligation under §312.53 to select and qualify those additional investigators and monitor their conduct of the study — the same obligation a commercial sponsor has toward its sites, just carried by the originating academic investigator instead.
Does grant or company funding change whether a study is investigator-initiated?
Not by itself. What determines IIS status is who holds the IND/IDE and the sponsor role, not the funding source. A study an investigator designed and sponsors can remain investigator-initiated even with company-donated drug supply or a company research grant, as long as the company has not taken over IND/IDE sponsorship.
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Investigator-Initiated Study (IIS)"
vocab-term-identifier="https://casrai.org/dictionary/term/investigator-initiated-study-iis" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/investigator-initiated-study-iis",
"name": "Investigator-Initiated Study (IIS)",
"identifier": "https://casrai.org/dictionary/term/investigator-initiated-study-iis",
"description": "An investigator-initiated study (IIS), also called an investigator-initiated trial (IIT), is a clinical trial that an individual investigator -- not a pharmaceutical or device company -- designs, initiates, and holds primary regulatory responsibility for conducting. The distinguishing test is not whether an academic clinician is involved (nearly every clinical trial has one), but who originates the protocol and holds the regulatory authorization to conduct it: the Investigational New Drug (IND) application for a US drug/biologic trial, or the Investigational Device Exemption (IDE) for a device trial. Under 21 CFR 312.3, an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered, is a \"sponsor-investigator\" -- a single person who simultaneously carries the regulatory obligations FDA assigns to a sponsor (21 CFR 312 Subpart D, sections 312.50-312.59) and those assigned to an investigator (sections 312.60-312.69). 21 CFR 812.3 defines the equivalent role for device studies conducted under an IDE. This is what distinguishes an IIS from a physician serving only as a participating-site principal investigator in an industry-sponsored multi-site trial, where a company holds the IND/IDE and remains sponsor of record.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
"url": "https://casrai.org/dictionary/term/investigator-initiated-study-iis",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-17T17:08:29",
"inLanguage": "en"
}
